Jin Yang-gon, chair of the HLB Group board, was appointed CEO of HLB Innovation.
HLB Innovation said on the 1st that its board met and approved an agenda item appointing Chair Jin as CEO. The company said the personnel move is intended to speed up decision-making in its semiconductor and bio businesses. The previous CEO resigned for personal reasons.
As a result, the company adopted a co-CEO structure led by Chair Jin and CEO Brian Kim. Jin will oversee overall management and the semiconductor business, while Kim will lead the bio business.
HLB Innovation is currently working to streamline production processes, invest in equipment, and expand production capacity (CAPA) in the semiconductor division. It is increasing the share of lead frames for automotive sensors and power semiconductors and expanding its customer base.
In the bio division, it is developing a CAR-T platform through its U.S. subsidiary Verismo. Verismo is conducting phase 1 trials of the solid tumor therapy "SynKIR-110" and the blood cancer therapy "SynKIR-310," based on its KIR-CAR platform. Interim phase 1 results for SynKIR-310 are scheduled to be released in the second half of this year.